BCL2 and Huntington disease: Inhibition of miR-181 and the expression of Bcl-2 aggravated, while the expression of Beclin1, LC3B, and Atg5 attenuated; the expressions of Bcl-2/Beclin1 signaling in the LBP-HD group have a similar effect to miR-181 inhibitor.